Biogen Reports Five-Year OPERA Data for Ocrevus in Relapsing Multiple Sclerosis

Biogen today presented five-year follow-up data from the Phase 3 OPERA I and II trials evaluating Ocrevus (ocrelizumab) in patients with relapsing multiple sclerosis. The data showed that Ocrevus maintained significant reductions in annualized relapse rates and MRI disease activity over five years of treatment.